Skip Ribbon Commands
Skip to main content

Impact of CIBMTR

Sharing knowledge. Sharing Hope.
Skip Navigation LinksHome   |   About CIBMTR   |   Impact of CIBMTR
  • Print
  • Share

Impact of CIBMTR

CIBMTR provides a unique resource of information and expertise to the medical and scientific community. Now with data on more than 425,000 patients, more than 1,000 publications, and more than 200 active research studies, CIBMTR is at the forefront of research to increase access to hematopoietic cell transplantation (HCT) and to improve outcomes.

Studies for evidence-based clinical decisions

CIBMTR studies use sophisticated statistical techniques and the power of large numbers to deal with the most timely and pressing issues in HCT. CIBMTR research has:
  • Determined outcomes of transplantation for rare diseases and new indications
  • Defined trends in transplantation activity, such as increased use and success in older patients
  • Identified factors affecting transplant outcomes, such as age, stage of disease and conditioning regimens
  • Determined efficacy of various donor types (including sibling, unrelated, and autologous) and graft sources (including cord blood, marrow, and peripheral blood)
  • Compared transplant and non-transplant treatments
  • Assessed long-term quality of life and late complications after transplantation

Collaboration and dedication

This research is possible because of the dedication of thousands of hours of voluntary effort from physicians and scientists, and their commitment to submit high quality data to the CIBMTR, and to propose and implement studies using those data.
The unusually inclusive nature of the CIBMTR Working Committees and data access policies means that CIBMTR data are available to a broad range of investigators in the field and, in a meaningful way, to physicians and patients dealing with difficult clinical decisions.

Initiatives and resources to advance the field

In addition to our large Research Database, the CIBMTR provides multiple other resources important for worldwide HCT research. Some of these are:
  • A prospective clinical trial network focused on hematopoietic cell transplantation research.
  • A repository of donor and recipient cells and DNA.
  • Innovative biostatistical methodologies for analyzing HCT.
  • Collaboration with worldwide organizations to exchange and increase data worldwide
  • CIBMTR is a founding member of the Worldwide Network for Blood and Marrow Transplantation.
  • Expertise in Health Services Research methodology and qualitative analysis. 
CIBMTR also strives to make the results of our research available to clinicians and patients to improve outcomes and quality of life through publications, guidelines and reference resources (accessible in the Reference Center).

View current and planned studies
Support our research
Last Updated: 2/28/2017 10:48 AM